Odds of vertebral compression fractures or surgical intervention were significantly lower among GLP-1 RA users ...

GLP-1 RA therapy linked to significantly lower risk for epilepsy compared with DPP4-i use among adults with T2DM.

The study addresses a critical clinical question, as patients with type 2 diabetes mellitus (T2DM) face a substantially ...

GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes.

For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use ...

Treatment with glucagon-like peptide-1 receptor agonists was associated with lower probabilities of heart, kidney, and lung complications after partial nephrectomy for RCC.

Weight loss drugs known as GLP-1 receptor agonists are sometimes referred to as “miracle drugs,” not only because they help people lose weight, but because they’ve also been shown to help with many ...

Hispanic, Black non-Hispanic, White non-Hispanic adults more likely to use GLP-1 RA injectables than Asian non-Hispanics. (HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes ...

GLP-1 RA use was associated with significant weight loss in patients with IBD and obesity and/or T2D, with mean differences of -9.1 kg in semaglutide users, -9 kg in liraglutide users, and -11.6 kg in ...

GLP-1 RAs are safe and efficacious for adults with IBD, with no increased risk for flare-ups, hospitalization, corticosteroid use, or operation.

Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...